Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 12/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | AKT2 | P31751 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7216630 | 0.89 | PTGS2 (0.50) | ROCK2PIM1GSK3BPTGS2MAPT | |
| SCHEMBL7218013 | 0.87 | PTGS2 (0.50) | ROCK2PIM1GSK3BPTGS2MAPT | |
| SCHEMBL7221448 | 0.86 | PTGS2 (0.60) | ROCK2PIM1GSK3BPTGS2AKT1 | |
| SCHEMBL5263797 | 0.86 | PTGS2 (0.60) | ROCK2PIM1GSK3BPTGS2AKT1 | |
| SCHEMBL7217077 | 0.84 | PTGS2 (0.60) | PTGS2AKT1AKT2PTGS1 | |
| SCHEMBL5261262 | 0.84 | PTGS2 (0.60) | PTGS2AKT1AKT2PTGS1 | |
| SCHEMBL5261561 | 0.84 | KDM4E (0.59) | ROCK2PIM1GSK3BPTGS2AKT1 | |
| SCHEMBL7220519 | 0.84 | KDM4E (0.59) | ROCK2PIM1GSK3BPTGS2AKT1 | |
| SCHEMBL7220425 | 0.84 | PTGS2 (0.49) | ROCK2PIM1GSK3BPTGS2MAPT | |
| SCHEMBL7215338 | 0.84 | PTGS2 (0.46) | PTGS2AKT1AKT2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6670365-B1 | Treatment of inflamation and/or cyclooxygenase-mediated diseases, reduced ulcerogenic effects; 2-phenyl-3-(4-methylsulfonylphenyl)imidazo(1,2-a)pyrimidine | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2003-12-30 | — | — | US | claimed |
| EP-1104762-B1 | SUBSTITUTED IMIDAZO[1,2A]AZINES AS SELECTIVE INHIBITORS OF COX-2 | S A L V A T LAB SA (ES) | 2002-09-18 | — | — | EP | claimed |
| EP-1104762-A1 | SUBSTITUTED IMIDAZO 1,2A]AZINES AS SELECTIVE INHIBOTORS OF COX-2 | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2001-06-06 | — | — | EP | claimed |
| US-6670365-B1 | Treatment of inflamation and/or cyclooxygenase-mediated diseases, reduced ulcerogenic effects; 2-phenyl-3-(4-methylsulfonylphenyl)imidazo(1,2-a)pyrimidine | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2003-12-30 | — | — | US | disclosed |
| EP-1104762-B1 | SUBSTITUTED IMIDAZO[1,2A]AZINES AS SELECTIVE INHIBITORS OF COX-2 | S A L V A T LAB SA (ES) | 2002-09-18 | — | — | EP | disclosed |